在阿尔茨海默氏病中的β-粉样蛋白和细胞之间的相互作用
You-Yue Li1,2, Dan-Dan Guo1, Ruo-Nan Duan1
1Department of Neurology, Qilu Hospital of Shandong University, 250012 Jinan, Shandong, China.
Frontiers in bioscience (Landmark edition)
|April 29, 2024
概括
在阿尔茨海默氏症 (AD) 中,细胞损失会破坏血脑屏障和Aβ清除,加速神经退行. 准细胞-Aβ相互作用为AD提供了新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 血管生物学 血管生物学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,与粉样β (Aβ) 斑块和神经纤维状结有关.
- 血管功能障碍,特别是细胞周细胞损失,越来越多地被认为是AD病变发生的关键因素.
- 细胞对于维持血脑屏障 (BBB),调节大脑血流 (CBF) 和清除大脑废物至关重要.
研究的目的:
- 审查细胞细胞在神经血管单元 (NVU) 中的作用及其在阿尔茨海默病中的功能障碍.
- 为了阐明AD中皮质细胞和粉样β (Aβ) 之间的复杂相互作用.
- 探索针对AD预防和治疗的细胞的治疗策略.
主要方法:
- 对皮细胞生物学,AD病理学和神经血管相互作用研究的文献综述.
- 分析Aβ影响细胞周围细胞功能和存活的机制.
- 综合当前和潜在的治疗方法,重点关注AD中的细胞.
主要成果:
- 细胞损失损害了BBB完整性,减少了Aβ清除,并加剧了Aβ沉积,创造了一个有害的循环.
- Aβ直接与皮细胞相互作用,导致它们的收缩,脱落和死亡.
- 细胞功能障碍对AD的神经元损失和认知衰退有显著的贡献.
结论:
- 细胞是大脑平衡的关键调节者,它们的功能障碍是阿尔茨海默病的中心机制.
- 了解围细胞-Aβ轴对于开发有效的AD疗法至关重要.
- 向围细胞介导通路是预防和治疗阿尔茨海默病的有希望的策略.
相关概念视频
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183


